Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis. RESEARCH DESIGN AND METHODS: After continuous infusion of low (300 pmol · kg−1 · day−1) or high (24 nmol · kg−1 · day−1) dose of exendin-4 in C57BL/6 or apolipoprotein E–deficient mice (apoE−/−), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes. RESULTS: Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE−/− mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-α and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-κB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI14-22, a protein kinase A–specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b. CONCLUSIONS: Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“Within the cardiovascular system, GLP-1 receptors are expressed on endothelial cells, monocytes, macrophages, and vascular smooth muscle cells (VSMCs) [9].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Similar to lung and pancreatic -cells (24), mice peritoneal macrophages and vascular smooth muscle cells abundantly expressed GLP-1 receptor protein, and the expression level was higher than in freshly isolated endothelial cells.”
ResultGu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575 · cited 1×
“Both TNF- – and MCP-1–deficient mice have significantly reduced atherosclerotic lesions (29,30).”
BackgroundA major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V., Gutierrez-Ramos, J.-C., Connelly, P. W., & Milstone, D. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11871 · Cited by 1,217 · cited 2×
“The adhesion of circulating monocytes to the intimal endothelial cells is thought to be one of the earliest events in the complex pathological process of atherosclerogenesis (14; 15).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“In vascular endothelial cells, GLP-1 stimulates NO production, which may explain the vasodilatory effects in mesenteric arteries (11) and pulmonary artery rings (12).”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundEbato, C., Uchida, T., Arakawa, M., Komatsu, M., Ueno, T., Komiya, K., Azuma, K., Hirose, T., Tanaka, K., Kominami, E., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.009 · Cited by 774 · cited 2×
“) or rabbit anti–glyceraldehyde-3-phosphate dehydrogenase antibody (Cell Signaling Technology, Beverly, MA) as described previously (16).”
BackgroundMethodSelf-citationNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
Background
Cited by
Items 201–300 of 560
Gut microbiota: a promising target against cardiometabolic diseases
Warmbrunn, M. V., Herrema, H., Aron-Wisnewsky, J., Soeters, M. R., Van Raalte, D. H., & Nieuwdorp, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1720511 · Cited by 47
Hwang, H., Chung, H. S., Jung, T. W., Ryu, J. Y., Hong, H. C., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., Choi, D. S., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.01.025 · Cited by 54
Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48
GLP-1 Receptor: A New Target for Sepsis
Yang, F., Zeng, F., Luo, X., Lei, Y., Li, J., Lu, S., Huang, X., Lan, Y., & Liu, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706908 · Cited by 48
“GLP-1 receptor is also expressed in CD14-positive monocytes of healthy people (Arakawa et al., 2010).”
BackgroundWei, J., Yang, B., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007980 · Cited by 44
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Terawaki, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Takahashi, H., Tanaka, T., Murase, K., Nagaishi, R., Tanabe, M., & Yanase, T. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-9752811371415510 · Cited by 48
Self-citationLi, J., Zheng, J., Wang, S., Lau, H. K., Fathi, A., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00015 · Cited by 47
“Another GLP-1 receptor agonist, exendin-4, was reported to reduce the accumulation of monocytes/macrophages in the arterial wall of ApoE−/− mice partly through activation of the cAMP/PKA pathway, which may contribute to attenuation of atherosclerosis (Arakawa et al., 2010).”
BackgroundLim, S., Oh, T. J., Dawson, J., & Sattar, N. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13850 · Cited by 45
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
Tsutsumi, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Terawaki, Y., Tanaka, T., Murase, K., Motonaga, R., Tanabe, M., & Yanase, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139709 · Cited by 50
Self-citationIncretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
“found that exendin-4 reduced monocyte adhesion to the endothelium of aorta, thereby leading to the suppression of atherosclerotic lesions in apoE knockout mice [95].”
BackgroundWang, Q., Jiang, Y., Luo, X., Wang, C., Wang, N., He, H., Zhang, T., & Chen, L. (2020) · Marine Drugs · doi:10.3390/md18010069 · Cited by 47
“Additionally, GLP-1 may improve insulin sensitivity in patients with type 2 diabetes and animal models [35].”
BackgroundKawai, Y., Uneda, K., Yamada, T., Kinguchi, S., Kobayashi, K., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109146 · Cited by 49
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
Mima, A. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1379274 · Cited by 48
Direct cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
The role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
Huang, J., Yi, H., Zhao, C., Zhang, Y., Zhu, L., Liu, B., He, P., & Zhou, M. (2018) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s175145 · Cited by 43
“Liraglutide (LIR), a GLP-1 analog, is a clinically used drug for metabolic syndromes with a wide knowledge in improving insulin sensitivity and anti-inflammatory function.(13,14) In COPD, it has been found that activation of GLP-1R signaling by LIR could decrease the severity of AECOPD and airway remodeling,(15,16) bu…”
Chang, S., Kim, D., Ryu, G. R., Ko, S., Jeong, I., Ahn, Y., Jo, Y., & Kim, M. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24425 · Cited by 44
“In addition, EX-4 inhibited the expressionsof inflammatorymediators TNF-a,monocyte chemoattractant protein-1 and IL-1b in macrophage cells [Arakawa et al., 2010; Kodera et al., 2011].”
BackgroundForst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/635472 · Cited by 44
“Treatment with Exenatide significantly inhibited monocyte adhesion in the aorta of C57BL/6 mice [85].”
BackgroundEffects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
Kitaura, H., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., Kinjo, R., Ma, J., Kanou, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126578 · Cited by 45
Fisetin-treatment alleviates airway inflammation through inhbition of MyD88/NF-κB signaling pathway
Huang, W., Li, M., Xia, M.-Y., & Jian-ying, S. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3582 · Cited by 54
Heinonen, S. E., Genové, G., Bengtsson, E., Hübschle, T., Åkesson, L., Hiss, K., Benardeau, A. M., Ylä‐Herttuala, S., Jönsson‐Rylander, A., & Gomez, M. F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/404085 · Cited by 44
“In ApoE −/− mice, similar findings have been made in many [97– 102], but not all studies [91].”
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Bułdak, Ł., Łabuzek, K., Bułdak, R. J., Machnik, G., Bołdys, A., & Okopień, B. (2015) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-015-1124-3 · Cited by 44
“phenotype induced by exenatide in endothelial cells and macrophages (Arakawa et al. 2010).”
GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats
Ku, H.-C., Chen, W., & Su, M. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0559-9 · Cited by 45
“It was reported previously that exendin-4 suppresses LPS-induced mRNA expression of TNFα, MCP1, and NFκB translocation to the nucleus in macrophage (Arakawa et al. 2010), and the effect is reversed by PKA-specific inhibitor.”
Lu, H. Y., Huang, C., Shih, C. M., Chang, W. H., Tsai, C.-S., Lin, F., & Shih, C. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121077 · Cited by 47
Akita, K., Isoda, K., Shimada, K., & Daida, H. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001469 · Cited by 43
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 44
Luo, Y., Yang, P., Li, Z., Luo, Y., Shen, J., Li, R., Zheng, H., Liang, Y., & Xia, N. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s224688 · Cited by 44
Sanada, J., Obata, A., Obata, Y., Fushimi, Y., Shimoda, M., Kohara, K., Nakanishi, S., Mune, T., Kaku, K., & Kaneto, H. (2021) · Scientific Reports · doi:10.1038/s41598-020-80894-x · Cited by 41
Herzlinger, S., & Horton, E. S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.009 · Cited by 46
Abdesselam, I., Pepino, P., Troalen, T., Macia, M., Ancel, P., Masi, B., Fourny, N., Gaborit, B., Giannesini, B., Kober, F., et al. (2015) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-015-0198-x · Cited by 42
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
Tanaka, M., Matsuo, Y., Yamakage, H., Masuda, S., Terada, Y., Muranaka, K., Wada, H., Hasegawa, K., Shimatsu, A., & Satoh‐Asahara, N. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.009 · Cited by 42
“The effect of exendin-4 (Ex-4; Abcam plc, Cambridge, UK) or Torin1 (Merck Millipore, Billerica, MA) on lipid accumulation was examined as reported previously with slight modifications [3,25].”
BackgroundMethodInfluentialMaiseyeu, A., Di, L., Ravodina, A. M., Barajas‐Espinosa, A. R., Sakamoto, A., Chaplin, A. M. L., Zhong, J., Gao, H., Mignery, M., Narula, N., et al. (2022) · Theranostics · doi:10.7150/thno.66456 · Cited by 42
Maintenance of Enteral ACE2 Prevents Diabetic Retinopathy in Type 1 Diabetes
Prasad, R., Floyd, J. L., Dupont, M., Harbour, A., Adu-Agyeiwaah, Y., Asare‐Bediako, B., Chakraborty, D., Kichler, K., Rohella, A., Calzi, S. L., et al. (2022) · Circulation Research · doi:10.1161/circresaha.122.322003 · Cited by 45
Skrobucha, A., Pindlowski, P., Krajewska, N., Grabowski, M., & Jonik, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1446468 · Cited by 42
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 42
Inoue, K., Maeda, N., Fujishima, Y., Fukuda, S., Nagao, H., Yamaoka, M., Hirata, A., Nishizawa, H., Funahashi, T., & Shimomura, I. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-95 · Cited by 42
“GLP-1 receptor activation has revealed the cardiovascular protection [18,19] and thus GLP-1 receptor agonist may be considered a promising new agent for the treatment of cardiovascular diseases linked to obese type 2 diabetes [20,21].”
BackgroundHe, J., Wang, C., Sun, Y., Lu, B., Cui, J., Dong, N., Zhang, M., LIU, Y., & Yu, B. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2509 · Cited by 41
Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus: A Role in Cardiovascular Disease
Smilowitz, N. R., Donnino, R. M., & Schwartzbard, A. Z. (2014) · Circulation · doi:10.1161/circulationaha.113.006985 · Cited by 43
“Preclinical studies of GLP-1 agonists in a mouse model demonstrate decreases in vascular inflammatory markers and monocyte/ macrophage accumulation in the arterial wall.(66)”
BackgroundLebherz, C., Kahles, F., Piotrowski, K., Vogeser, M., Foldenauer, A. C., Nassau, K., Kilger, E., Marx, N., Parhofer, K. G., & Lehrke, M. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0330-8 · Cited by 39
Manavi, M. A. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102250 · Cited by 40
Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus
Rodríguez Jiménez, B., Rodríguez de Vera Gómez, P., Belmonte Lomas, S., Mesa Díaz, Á. M., Caballero Mateos, I., Galán, I., Morales Portillo, C., & Martínez-Brocca, M. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1386542 · Cited by 39
Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway
Zhan, J., Tan, P., Wang, Y., Wang, Y., He, J., Tang, Z.-Y., Huang, W., & Liu, Y. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-6481332511368690 · Cited by 40
Ke, J., Liu, Y., Yang, J., Lu, R., Tian, Q., Hou, W., Wang, G., Wei, R., & Hong, T. (2017) · Scientific Reports · doi:10.1038/srep41085 · Cited by 38
“GLP-1R and its downstream PKA signalling are known as the mediators in most of the GLP-1 actions 15 .”
Shigeoka, T., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Horikawa, T., Tanaka, T., Irie, S., Motonaga, R., Hamanoue, N., Tanabe, M., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13247 · Cited by 39
Self-citationTsai, T.-H., Lee, C.-H., Cheng, C.-I., Fang, Y.-N., Chung, S.-Y., Chen, S.-M., Lin, C.-J., Wu, C.-J., Hang, C.-L., & Chen, W.-Y. (2019) · Cells · doi:10.3390/cells8060589 · Cited by 37
“Recently, a GLP-1 agonist has been found to attenuate atherosclerotic lesions and endothelial function by inhibiting the inflammation process [18,19].”
BackgroundCardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Pleiotropic effects of incretins
Gupta, V. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94259 · Cited by 36
“The net result seems to be amelioration of endothelial function and stabilization of fatty plaques, which should eventually translate into direct protective effects of GLP-1 on the progression of atherosclerosis.[49-54] 4.”
BackgroundZhou, W., Shao, W., Zhang, Y., Liu, D., Liu, M., & Jin, T. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00292.2020 · Cited by 36
“The anti-inflammatory and anti-oxidative stress effect of GLP-1 and GLP-based drugs were then demonstrated by several preclinical investigations (2, 22, 32, 41).”
BackgroundDorecka, M., Siemianowicz, K., Francuz, T., Garczorz, W., Chyra, A., Klych, A., & Romaniuk, W. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71069-7 · Cited by 36
Battistoni, A., Piras, L., Tartaglia, N., Carrano, F. M., Vitis, C. D., & Barbato, E. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1669685 · Cited by 49
Hirano, T., Yamashita, S., Takahashi, M., Hashimoto, H., Mori, Y., & Goto, M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.010 · Cited by 39
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
Zhong, J., Chen, H., Liu, Q., Zhou, S., Liu, Z., & Xiao, Y. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.12.007 · Cited by 36
“Abundant GLP-1 R is present in the macrophage-rich regions of atherosclerotic plaques, suggesting that GLP-1 RAs could interact with macrophages to attenuate their activation, recruitment and accumulation in the arterial wall [113,114].”
BackgroundIncretin-based therapies and cardiovascular risk
Mannucci, E., & Dicembrini, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.678940 · Cited by 35
Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
Rizzo, M., Nikolić, D., Banach, M., Patti, A. M., Montalto, G., & Rizvi, A. A. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131206102255 · Cited by 36
“Experimental data indicate that exenatide attenuates atherosclerotic lesions in a mouse model [57] along with reducing monocyte/macrophage accumulation in the arterial wall, indicating that suppression of vascular inflammation may represent a direct cardiovascular benefit of IBTs.”
BackgroundRobinson, E., Tate, M., Lockhart, S. M., McPeake, C., O’Neill, K. M., Edgar, K. S., Calderwood, D., Green, B. D., McDermott, B. J., & Grieve, D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0386-5 · Cited by 39
Pereira, C. A., Carneiro, F. S., Matsumoto, T., & Tostes, R. C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13054 · Cited by 40
Diabetic endothelial microangiopathy and pulmonary dysfunction
Zhang, L., Jiang, F., Xie, Y., Mo, Y., Zhang, X., & Liu, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1073878 · Cited by 37
“GLP-1 decreased reactive oxygen species-induced senescence in human umbilical vein endothelial cells (HUVECs) in a receptor-dependent manner that included downstream Protein kinase cAMP-dependent (PKA) signaling and the activation of antioxidant genes (40).”
BackgroundJin, W. L., Azuma, K., Mita, T., Goto, H., Kanazawa, A., Shimizu, T., Ikeda, F., Fujitani, Y., Hirose, T., Kawamori, R., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2141-5 · Cited by 40
“Nuclear protein extracts were isolated from HUVEC and nuclear factor-κB (NF-κB) p65 content was determined by specific ELISA kit (Imgenex, San Diego, CA, USA) as described previously [18].”
MethodSelf-citationPetersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 37
“GLP-1 has shown protective effects on cardiovascular function in both apolipoprotein E (APO E) knockout mice and humans making the underlying mechanisms of these effects relevant to investigate [72, 150-152].”
BackgroundZhou, L., Xu, Z., Oh, Y., Gamuyao, R., Lee, G., Xie, Y., Cho, H., Lee, S., & Duh, E. J. (2021) · JCI Insight · doi:10.1172/jci.insight.93382 · Cited by 34
Abdelwahed, O. M., Tork, O. M., el Din, M. G., Rashed, L. A., & Zickri, M. B. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.02.002 · Cited by 37
Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity
Kimura, T., Obata, A., Shimoda, M., Shimizu, I., Xavier, G. D. S., Okauchi, S., Hirukawa, H., Kohara, K., Mune, T., Moriuchi, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28849-1 · Cited by 37
Koska, J., Migrino, R. Q., Chan, K. C., Cooper-Cox, K., & Reaven, P. D. (2021) · Diabetes Care · doi:10.2337/dc20-2014 · Cited by 31
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“For example, continuous infusion of exendin-4 in both wild-type and apolipoprotein E-deficient normoglycaemic mice was reported to decrease monocyte adhesion and development of atherosclerotic lesions in thoracic aorta, effects proposed to occur via cAMP/PKA-dependent suppression of inflammation (Arakawa et al., 2010).”
BackgroundJonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
Inaba, W., Mizukami, H., Kamata, K., Takahashi, K., Tsuboi, K., & Yagihashi, S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.07.030 · Cited by 36
“In fact, exenatide was recently shown to protect against inflammatory process of atherosclerotic lesions and renal injury in diabetic animals independent of hyperglycemia (Arakawa et al., 2010; Kodera et al., 2011).”
BackgroundSun, Y., He, L., Yan, M., Zhao, R.-Q., Li, B., Wang, F., Yang, Y., & Yu, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6618 · Cited by 33
“GLP‐1 serves a role in inflammation and may inhibit lipopolysaccharide (LPS)‐induced cytokine secretion in various types of cells, including peritoneal macrophages and cortical astrocytes (19-21).”
Wu, Q., Li, D., Huang, C., Zhang, G., Wang, Z., Liu, J., Yu, H., Song, B., Zhang, N., Li, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113517 · Cited by 34
PATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Patel, K., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0189 · Cited by 33
Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation
Li, A. Q., Zhao, L., Zhou, T. F., Zhang, M. Q., & Qin, X. M. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00249.2014 · Cited by 32
Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease
Lodge, M., Dykes, R., & Kennedy, A. J. (2024) · Biomolecules · doi:10.3390/biom14070845 · Cited by 38
“Boland et al. demonstrated that the GLP-1 receptors also are expressed on mouse and human monocytes and macrophages [186].”
BackgroundDiabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies
Addison, D., & Aguilar, D. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0153-0 · Cited by 36
“Exendin-4 appears to regulate this inflammatory response via the cAMP/PKA pathway, which subsequently inhibits pro-inflammatory cytokines such as tumor necrosis factor-α and monocyte chemoattractant protein-1 [34].”
BackgroundTakai, S., Sakonjo, H., & Jin, D. (2014) · Journal of Pharmacological Sciences · doi:10.1254/jphs.14052fp · Cited by 34
Yao, Y., Zaw, A. M., Anderson, D. E. J., Jeong, Y., Kunihiro, J., Hinds, M. T., & Yim, E. K. F. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.10.011 · Cited by 34
Alexiadou, K., Hartley, A., Tan, T. M.-M., & Khamis, R. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.03.003 · Cited by 31
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
“Exenatide reduces monocyte adhesion and infiltration into mouse aortic tissue by suppressing VCAM-1 and ICAM-1 expression [153,154].”
Gonçalves, A., de Almeida, L. C. G., Silva, A. P., Ribeiro, C., Ambrósio, A. F., Cristóvão, A. J., & Fernandes, R. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.144 · Cited by 31
Berndt, J., Ooi, S. L., & Pak, S. C. (2021) · Molecules · doi:10.3390/molecules26164822 · Cited by 33
AL-Qabbaa, S. M., Qaboli, S. I., Alshammari, T. K., Alamin, M. A., Alrajeh, H. M., Almuthnabi, L. A., Alotaibi, R. R., Alonazi, A. S., Dayel, A. F. B., Al‐Rasheed, N. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076532 · Cited by 33
“Therefore, by incr asing the concentration of active GLP-1, s tagliptin may synergistically reduce inflammation in abetic kidneys [44,45].”
BackgroundDo incretins improve endothelial function?
Oyama, J., Higashi, Y., & Node, K. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-21 · Cited by 37
Cai, Y., Hu, X., Yi, B., Zhang, T., & Wen, Z. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1961-9 · Cited by 31
“Recent studies have demonstrated that GLP-1 exerts beneficial effects through its anti-inflammatory property [15–17].”
BackgroundPleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 32
Li, P., Tang, Z., Wang, L., & Feng, B. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6978 · Cited by 29
“The majority of studies have demonstrated that GLP-1 reduces vascular inflammation via suppression of pro-inflammatory activation of monocytes/macrophages (18).”
Zhang, C., Qian, D., Zhao, H., Lv, N., Yu, P., & Sun, Z. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.012 · Cited by 30
Dipeptidyl Peptidase-4 Inhibitor
Murohara, T. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.050 · Cited by 32
Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach
Fularski, P., Czarnik, W., Dąbek, B., Lisińska, W., Radzioch, E., Witkowska, A., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105212 · Cited by 30
The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis
Terawaki, Y., Nomiyama, T., Akehi, Y., Takenoshita, H., Nagaishi, R., Tsutsumi, Y., Murase, K., Nagasako, H., Hamanoue, N., Sugimoto, K., et al. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-10 · Cited by 29
Self-citationLi, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 31
“Studies showed that exendin-4 can prevent lipopolysaccharide (LPS)-induced cytokine and chemokine mRNA synthesis in both human and mouse monocytes (Arakawa et al., 2010) and also”
BackgroundLaminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion
Yang, L., Wang, L., Zhu, C., Wu, J., Yuan, Y., Yu, L., Xu, Y., Xu, J., Wang, T., Liao, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19957 · Cited by 28
“Therefore, some GLP-1 analogues have been approved for the treatment of diabetes and obesity [10, 11].”
Wang, Z., Wang, M., Hu, X.-F., Li, Y., Ma, D., Li, S.-L., Zhao, G., Xie, Y., Shu, Y., & Yang, J. (2018) · Transplantation · doi:10.1097/tp.0000000000002448 · Cited by 30
Koshibu, M., Mori, Y., Saito, T., Kushima, H., Hiromura, M., Terasaki, M., Takada, M., Fukui, T., & Hirano, T. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00511.2018 · Cited by 27
Fedorova, N. V., Ksenofontov, A. L., Serebryakova, M. V., Stadnichuk, V. I., Gaponova, T. V., Baratova, L. A., Sud’ina, G. F., & Galkina, S. I. (2018) · Mediators of Inflammation · doi:10.1155/2018/1574928 · Cited by 28
“Prevention of vascular adhesion of monocytes contributes to the cardiovascular protective effect of GLP-1 analogs [23, 24].”
SLEVIN, M. A., Iemma, R. S., Zeinolabediny, Y., Liu, D., Ferris, G. R., Caprio, V. E., Phillips, N., Napoli, M. D., Guo, B., Zeng, X., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02124 · Cited by 30
Exendin-4 protects rat islets against loss of viability and function induced by brain death
Carlessi, R., Lemos, N. E., Dias, A. L., de Oliveira, F. S., Brondani, L. D. A., Canani, L. H. S., Bauer, A. C., Leitão, C. B., & Crispim, D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.05.009 · Cited by 29
“In agreement with this hypothesis, exendin-4 has previously been shown to mitigate monocyte infiltration and expression of adhesion molecules in a mouse model of atherosclerosis (Arakawa et al., 2010).”
Chen, J., Mei, A., Liu, X., Braunstein, Z., Wei, Y., Wang, B., Duan, L., Rao, X., Rajagopalan, S., Dong, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.772446 · Cited by 29
Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
García‐Vega, D., González‐Juanatey, J. R., & Eirás, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 26
“GLP-1 agonists can reduce inflammatory mediators [231] and monocyte adhesion to endothelial cells [232].”
BackgroundCombined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
Ying, Z., van Eenige, R., Ge, X., van Marwijk, C., Lambooij, J. M., Guigas, B., Giera, M. A., de Boer, J. F., Coşkun, T., Qu, H., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104684 · Cited by 28
la Tijera, F. H., & Servín-Caamaño, A. I. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i10.1297 · Cited by 29
Metadata
- Authors
- Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H.
- Affiliations
- Juntendo University (JP)
- Corresponding author
- Mita, Tomoya
- Watada, Hirotaka
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-01-12
- Volume
- 59
- Issue
- 4
- Pages
- 1030-1037
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2844811
- OpenAlex
- W2142097676
- Cited by
- 548
- References
- 38
- Citations by year
- 2026: 31 · 2025: 25 · 2024: 34 · 2023: 27 · 2022: 37 · 2021: 33 · 2020: 27 · 2019: 25 · 2018: 36 · 2017: 32 · 2016: 41 · 2015: 46 · 2014: 36 · 2013: 35 · 2012: 43
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- exendin-4, GLP-1 receptor agonists, monocyte adhesion, endothelial cells, atherosclerosis, macrophage accumulation, ApoE-deficient mice, NF-κB, TNF-α, MCP-1, cAMP signaling, protein kinase A, CD11b, inflammation
- MeSH terms
- Exenatide, Animals, Aorta, Cell Adhesion, Endothelium, Vascular, Flow Cytometry, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Islets of Langerhans, Liver, Lung, Male, Mice, Inbred C57BL, Monocytes, Peptides, Venoms, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.